Department of Oncology, Wayne State University School of Medicine, Karmanos Cancer Institute, 4100 John R, Detroit, MI, 48201, USA.
Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Mol Cancer. 2021 Jun 1;20(1):82. doi: 10.1186/s12943-021-01371-1.
Liquid biopsy is now considered a valuable diagnostic tool for advanced metastatic non-small cell lung cancer (NSCLC). In NSCLC, circulating tumor DNA (ctDNA) analysis has been shown to increase the chances of identifying the presence of targetable mutations and has been adopted by many clinicians owing to its low risk. Serial monitoring of ctDNA may also help assess the treatment response or for monitoring relapse. As the presence of detectable plasma ctDNA post-surgery likely indicates residual tumor burden, studies have been performed to quantify plasma ctDNA to assess minimal residual disease (MRD) in early-stage resected NSCLC. Most data on utilizing liquid biopsy for monitoring MRD in early-stage NSCLC are from small-scale studies using ctDNA. Here, we review the recent research on liquid biopsy in NSCLC, not limited to ctDNA, and focus on novel methods such as micro RNAs (miRNA) and long non-coding (lncRNA).
液体活检现在被认为是晚期转移性非小细胞肺癌（NSCLC）有价值的诊断工具。在 NSCLC 中，循环肿瘤 DNA（ctDNA）分析已被证明可增加识别靶向突变的可能性，并且由于其风险低而被许多临床医生采用。ctDNA 的连续监测也有助于评估治疗反应或监测复发。由于手术后可检测到的血浆 ctDNA 可能表明存在残留肿瘤负担，因此已经进行了研究以定量血浆 ctDNA 来评估早期切除 NSCLC 的微小残留疾病（MRD）。利用液体活检监测早期 NSCLC 中 MRD 的大多数数据来自使用 ctDNA 的小规模研究。在这里，我们回顾了 NSCLC 中液体活检的最新研究，不仅限于 ctDNA，还重点介绍了 micro RNAs（miRNA）和长链非编码（lncRNA）等新方法。
